StageZero Life Sciences, Ltd Announces Q3 2023 Financial Results and Operational Update - Seite 2
Operational Update: further details will be provided during the Analyst Call.
Q3 2023 Financial Results
All amounts are expressed in U.S. dollars unless otherwise stated and results are reported in accordance with International Financial Reporting Standards.
The Company generated $2.2 million in cancer testing and treatment revenue for the nine months ended September 30, 2023 as compared to COVID testing-related revenue of $3.1 million for the nine months ended September 30, 2022 and realized a net loss of $3.0 million, or $0.03 basic and diluted loss per common share as compared to a $1.9 million net loss for the nine months ended September 30, 2022, or $0.02 basic and diluted loss per common share.
The Company generated $0.745 million in cancer testing and treatment revenue for the three-months ended September 30, 2023, compared to COVID testing-related and cancer treatment revenue of $0.799 million for the three months ended September 30, 2022. Net loss was $0.8 million, or $0.01 loss per fully diluted common share in Q3, 2023 as compared to a $0.05 million net loss, or $0.00 loss per fully diluted common share in Q3, 2022.
The Company's financial statements and management's discussion and analysis are available on www.sedar.com.
Analyst and Investor Call
Lesen Sie auch
Event Date: Wednesday November15, 2023
Time: 8:30 am ET
Webcast Link: https://www.webcaster4.com/Webcast/Page/2082/49467
Conference Call Numbers
Toll Free: 877-545-0320
International: 973-528-0002
Participant Access Code: 630757
About StageZero Life Sciences, Ltd.
StageZero Life Sciences, Ltd. is a company innovating on the forefront of screening for the early detection of cancer. StageZero combines its proprietary liquid biopsy multi-cancer detection test, Aristotle, with Physician led clinical programs; offering patients a unique treatment combination not found anywhere else.
Aristotle, is the first ever mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types.
Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. It is an individualized therapeutic approach which seeks to simultaneously target multiple metabolic cancer pathways and is intended for adjunctive administration alongside standard-of-care cancer therapy. The aim is to restrict cancer cell energy supply and use.